FOS and gastric cancer: Wong et al. reported that the cyclooxygenase-2 inhibitor (SC-236) functioned the antitumor effects via inhibiting JNK-c-Jun/AP-1 activation, and the inhibition of JNK activation may have a therapeutic benefit against gastric cancer [37].